RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS

The results show a 66% (6/9) objective response rate (ORR) with 44% (4/9) complete response (CR) 1 month after the treatment. Although progressive disease (PD) occurred in 8/9 patients at the end of observation period (2‐21 months, median 5 months), we achieved a mean survival time (MST) of 7 and 12 months in Groups 1 and 2, respectively. Three patients with stage III OMM survived from 5 months to 1 year and 2 of them were euthanized due to OMM‐unrelated reasons. The achieved survival times are longer than the reported survival times for stage III OMM treated with radical surgical excision alone (MST 3 months) or combined with radiotherapy (MST 5 months). In addition, we observed a decline in the percentage of regulatory T cells (Treg) in the peripheral blood in the course of treatment, which could be attributed to a systemic antitumor response due to IL‐12. No major side effects of the treatment were noted and the therapy was tolerated well by all patients.